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and metabolic functions, and circulating inflammatory
markers might help to better characterise these
patients.
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The diagnosis of COPD relies on the demonstration of
fixed airflow limitation in the absence of less frequent
diseases causing airways obstruction. Guidelines have
for decades used the ratio of FEV1/VC or FEV1/FVC as
the measurements of choice; this has rarely been the
cause of debate whereas the cut-off values for the ratio
have been intensely debated. The fixed ratio of 0.7
causes under-diagnosis of COPD in younger adults and
over-diagnosis in the elderly whereas the use of lower
limit of normal presumes that less than 5% of elderly
asymptomatic smokers can have COPD as ‘normality’ is
defined according to statistics only.
More importantly, however, the current diagnostic
guidance does not take into account that we define
COPD as 1) a disease characterised by an abnormal
inflammatory response, 2) a disease with a frequently
occurring extrapulmonary component – and 3) that we
know that one of the main subtypes of COPD,
emphysema, often does not lead to airflow limitation in
its earliest stages. We will need to decide whether we
want to keep our simple diagnostic criteria and sub-
sequently try to describe the individual patient’s
features by “sub-grouping” COPD or whether our
diagnostic criteria should mirror how we define the
disease.
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The most recent definition of COPD clearly states that
the disease is both preventable and treatable. The
knowledge on interventions that may improve the
clinical course of COPD is constantly expanding and the
COPD patients of today are facing a totally different
approach from the health professionals compared to the
situation 20 years ago. This means that the clinical
course of the disease need no longer result in a con-
tinuing decline of lung function, repeated exacerbations
and development of respiratory failure. Whereas
smoking cessation in the early stage of COPD and long
term oxygen treatment in the end-stage disease were in
the past thought to be the only two modalities affecting
the long term clinical course of the disease, it is now
documented that also pharmacological treatment with
long acting antimuscarinic agents, long acting beta-2-
agonists and inhaled corticosteroids, rehabilitation
comprising physical exercise and immunisation against
influenza affects the long term prognosis and improves
the health related quality of life of the patients. Also
the treatment of acute exacerbations with non-invasive
ventilation has revolutionised the clinical practice by
reducing both mortality and the need for intubation.
In order to implement these options with success, the
timing of intervention is essential. In this context the
more widespread use of spirometry, assessment of the
severity of dyspnea and identification of patients with
repeated exacerbation is mandatory. The pulmonary
community has a major obligation in assuring that the
knowledge from the successful controlled trials will be
implemented in the clinical practice.
ABSTRACTS - OTHER LECTURERS
Exhaled NO and systemic inflammation biomarkers in
COPD - a longitudinal study
N.B. Roberts, J. Vestbo and T.A. Gerds
Pulmonary Cardiology Department of Hvidovre
Hospital, Department of Biostatistics, Copenhagen
University, Denmark
E-mail address: nassim_dk@yahoo.com
The usefulness of exhaled nitric oxide (eNO) measure-
ment is still controversial in chronic obstructive pul-
monary disease (COPD). However, modelling measure-
ments of eNO from multiple flows may provide measures
of parenchymal and airway inflammation and could
potentially be used to monitor inflammation in COPD. In
my PhD study I will investigate any possible correlation
between local inflammation and systemic inflammation
in COPD patients and relate it to presence/development
of cardiac disease.
Ninety one (91) COPD patients recruited in the
ECLIPSE study with FEV1 ranging from 17-77% have been
seen every three months in the first year and every six
months in the following eighteen month period. I aim to
use two compartment nonlinear modelling of multiple
flow rates eNO at 10, 30, 50, 100 and 200 mL·s–1, but
currently only raw eNOs are available and eNO50 is used
to indicate airway inflammation. The following
biochemical markers of inflammation in serum are used:
IL-6, IL-8, TNFα, Clara cell secretory protein-16 (CC-16),
and Surfactant Protein D (SPD).
Neither eNO50 nor any of the systemic markers varied
according to age, gender or GOLD stage except IL6 which
increased by age. There was no correlation between
eNO50 and any of the systemic markers. There was an
association between TNFα and PARC (r=.26, p=.01) but no
other inter-relations between systemic markers. IL-6 was
significantly elevated in subjects with ischemic heart
disease (7.27 vs 2.13 pg/mL, p<.001) as was CC-16 (6.17
vs. 4.86 ng/mL, p=.03), none of the others markers were
related to heart disease at baseline.
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